2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Treatment Considerations, Combination Therapy, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Clinical Practice (Health Services and Quality), Clinical Guidelines, Practice Models, Diseases, Immunology, Neutropenia, Infectious Diseases, Lymphoid Malignancies, Lymphomas, Myeloid Malignancies, Measurable Residual Disease, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Young Adult
PAPER

5333 MRD-guided chemotherapy-free regimen with sonrotoclax, zanubrutinib, and zuberitamab in treatment-naïve mantle cell lymphoma (TRIUM): Promising early efficacy from the phase II study

Zhao Peiqi, MD, Fei Li, MD, PhD2, Jianxia He3, Pan Zhao4, Yulan Zhou5, Yinan Gao6, Xingli Zou7, Huilai Zhang, PhD8
1 State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine / Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin, China
2 The First Affiliated Hospital of Nanchang University, Jiangxi, China
3 Shanxi Provincial People's Hospital, Shanxi, China
4 Affiliated Hospital of North Sichuan Medical College, Sichuan, China
5 The First Affiliated Hospital of Nanchang University, Jiangxi, China
6 Shanxi Provincial People's Hospital, Taiyuan, China
7 Affiliated Hospital of North Sichuan Medical College, Sichuan, China
8 State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine / Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin, China

Introduction: Targeted therapy-based induction regimens provide novel treatment options for newly diagnosed mantle cell lymphoma (MCL). Recent studies have demonstrated the promising efficacy of triple-drug combinations comprising BCL-2 inhibitors, BTK inhibitors, and CD20 monoclonal antibodies (e.g., IVO, IVR, AVO, ZVO). Among these regimens, the combination of sonrotoclax, zanubrutinib, and an anti-CD20 antibody represents the first triplet approach integrating two next-generation targeted agents, potentially maximizing the therapeutic synergy of highly selective BCL-2 and BTK inhibition in MCL. Sonrotoclax, a next-generation BCL-2 inhibitor, exhibits higher selectivity and pharmacological potency than venetoclax. Zanubrutinib, a next-generation BTK inhibitor, has shown promising efficacy and safety profiles in patients with treatment-naïve (TN) MCL. This study aimed to evaluate the efficacy and safety of sonrotoclax-containing, chemotherapy-free triplet induction therapy followed by minimal residual disease (MRD)-guided maintenance treatment in TN MCL. Herein, we reported the preliminary results.

Methods: This open-label, single-arm, multicenter trial enrolled patients with TN MCL. Patients received zanubrutinib (160 mg BID) plus CD20 mAb (zuberitamab) for 2 cycles as lead-in treatment. Sonrotoclax was added at Cycle 3 Day 1 with dose escalation to target 320 mg daily. Triplet induction therapy continued through Cycle 12. After induction, patients who achieved complete remission (CR) with undetectable MRD (uMRD) and were classified as low-risk would receive 1 year of zanubrutinib monotherapy, followed by observation. Patients who achieved partial response (PR) or CR with MRD-positive or were considered as high-risk would receive 1 year of sonrotoclax in combination with zanubrutinib, followed by MRD reassessment. If uMRD was achieved thereafter, patients would proceed to observation; if MRD remained detectable, they would receive zanubrutinib maintenance therapy. Patients who meet any one of the features are considered as high risk, including blastoid histology, Ki-67 ≥30%, TP53 aberration, and simplified MIPI score >6. The primary endpoint was the CR rate after triplet induction. Secondary endpoints included ORR, PFS, OS, and MRD-negative rate.

Results: From Aug 2024 to Sep 2025, 34 patients were enrolled (median age 63 years [range 47-88]; 78% male). At baseline, 67.6% (23/34) of patients had stage III/IV disease, and 82.4% (28/34) had extranodal involvement. Twenty-five patients were high-risk: 76% (19/25) had high Ki-67, 56% (14/25) had high MIPI scores, and among the TP53 evaluable patients, 12% (3/25) had TP53 aberrations.

As of Jun 10, 2026, among 29 efficacy evaluable patients at cycle 12 (by PET-CT), 25 patients showed CR, 2 patients achieved PR, 1 patient had stable disease, and 1 patient experienced progressive disease. The CR rate was 86.2% and ORR was 93.1% after 12 cycles of induction. Twenty-eight patients underwent MRD assessment by multiparameter flow cytometry (sensitivity 10?4) in both peripheral blood and bone marrow at cycle 12, and 27 (96.4%) were MRD negative in both peripheral blood and bone marrow.

Twenty-six patients entered maintenance therapy; 24 received zanubrutinib plus sonrotoclax and 2 received zanubrutinib monotherapy.

With a median duration of treatment of 13.9 months (range, 3.0-21.9), the most common (≥10%) grade ≥3 adverse events were neutropenia (14.7%, 5/34) and lymphopenia (14.7%, 5/34). Treatment-related serious adverse events occurred in 2 patients (1 thrombocytopenia and 1 pleural effusion). No clinical or laboratory tumor lysis syndrome, atrial fibrillation/flutter, or additional sonrotoclax-related safety signals were observed.

Conclusions: The preliminary results indicate sonrotoclax combined with zanubrutinib and zuberitamab exhibits compelling antitumor activity with deep molecular responses and a manageable safety profile in patients with newly diagnosed MCL. This strategy offers a promising chemotherapy-sparing option, particularly for high-risk populations. The trial is ongoing, with further long-term efficacy and survival data forthcoming.

Zhao Peiqi, MD: No relevant conflicts of interest to declare.